DelveInsight's Exosome Therapies Market Insights report includes a comprehensive understanding of emerging exosome therapies, market share ...

Kerenida is currently approved to slow the progression of chronic kidney disease associated with type 2 diabetes. Bayer has submitted a supplemental new drug application (sNDA) for Kerendia ...

Capricor Therapeutics has completed its submission of a biologics license application (BLA) seeking U.S. approval of deramiocel, the company’s cell therapy for heart muscle disease in people with ...

“We believe that the strength of this application is that deramiocel has shown in multiple clinical trials attenuation of the cardiac implications of DMD. We look forward to working with the FDA ...

The firm's analyst highlighted the completion of a rolling Biologics License Application (BLA) filing with the U.S. Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy ...

Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.

Shares of Capricor Therapeutics CAPR gained 8.4% on Thursday following the completion of the submission of a biologics license application (BLA) to the FDA seeking full approval for deramiocel to ...